Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Luma Health Co vs Measured

Luma Health Co
Graded #62

Lower grade

vs+0.29999999999999716
Measured
Graded #58

Higher grade

The verdict

Measured takes it — 75.1/100 to 74.8/100, but only just.

Measured grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Metabolic-health membership pairing GLP-1 treatment with 1:1 nutrition support and board-certified provider care. Luma Health Co is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMeasured +18
68
86
Dose & formulationMeasured +8
69
77
Clinical oversightMeasured +4
83
87
Labs & monitoringLuma Health Co +34
97
63
FulfillmentLuma Health Co +3
70
67
Contract termsLuma Health Co +14
55
41
Luma Health Co · left barMeasured · right bar

The numbers

MetricLuma Health CoMeasured
WeighScore74.8/10075.1/100
GradeCC
Scorecard rank#62#58
Semaglutide$120/mo (plus a separate fee, compounded)$119/mo (compounded)
Tirzepatide$180/mo (compounded)$229/mo (compounded)
Coverage30 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Luma Health Co

Graded #62 · C

Strengths

  • Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
  • No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
  • Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
  • Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
  • HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission

Where it loses points

  • Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
  • Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
  • Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
  • Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Measured

Graded #58 · C

Strengths

  • Membership includes 1:1 nutrition support and board-certified provider care
  • Both compounded (from $79/mo microdose, $119 semaglutide, $229 tirzepatide) and brand-name Wegovy/Zepbound
  • Insurance or cash-pay options for brand-name medications
  • Oral option available (Wegovy pill); cancel-anytime membership

Where it loses points

  • Membership ($49/mo) is billed separately on top of medication cost
  • Compounded medications are not FDA-approved
  • Compounding/dispensing pharmacies not individually named
  • State availability not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard